Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)
Oct. 04, 2021 8:30 AM ETCyclacel Pharmaceuticals, Inc. (CYCC)
CEO Interviews
1.82K Followers
Summary
- Cyclacel is a biotech company developing small molecule drugs for treating cancer and other diseases.
- CEO Spiro Rombotis joined us for a discussion about cancer resistance and clinical trials.
- Investor updates including recent study of oral Fadraciclib in patients with advanced tumors and aggressive lymphomas.
Cyclacel (NASDAQ:CYCC) is a biotech company developing small molecule drugs for treating cancer and other diseases. CEO Spiro Rombotis joined us for a discussion about cancer resistance, clinical trials and investor updates.
Editor's Note: This article covers one or more microcap stocks. Please be aware of the risks associated with these stocks.
This article was written by
1.82K Followers
Quality leadership is a significant factor in successful companies. CEO Interviews brings you informed conversations with CEOs in the publicly traded markets. The show provides intimate and in-depth investing discussions with industry leaders across all sectors of the marketplace.
Recommended For You
Comments
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!